Navigation Links
Techne Corporation Releases Unaudited First Quarter Fiscal Year 2014 Results
Date:10/29/2013

MINNEAPOLIS, Oct. 29, 2013 /PRNewswire/ -- Techne Corporation's (NASDAQ: TECH) financial results for the quarter ended September 30, 2013 include the following highlights:

First quarter earnings were $27.4 million or $0.74 per diluted share.  Adjusted earnings for the quarter were $30.7 million (an increase of 11.6% from the prior fiscal year period) or $0.83 per diluted share.  Adjusted earnings and adjusted earnings per share exclude intangible asset amortization, costs recognized upon the sale of inventory that was written-up to fair value as part of acquisitions and professional fees related to an acquisition completed in fiscal 2014.Net sales as reported increased 14.2% to $85.7 million for the quarter ended September 30, 2013. Organic sales increased 5.1% in the quarter.  Organic sales exclude sales by Bionostics Holding Limited, which was acquired on July 22, 2013 for net cash of $103 million, and the impact of foreign currency exchange rate fluctuations. 

The Biotechnology segment includes sales made through R&D Systems' Biotechnology Division, R&D Europe, Tocris, R&D China, BiosPacific and Boston Biochem.  Biotechnology segment net sales were $73.2 million for the quarter ended September 30, 2013, an increase of 5.3% from $69.5 million for the quarter ended September 30, 2012.  Biotechnology sales increased 4.4% for the quarter ended September 30, 2013 excluding the impact of foreign currency exchange rate fluctuations.The table below shows changes to the components of organic sales for the Biotechnology segment, from the same prior-year period.Quarter Ended9/30/13U.S. industrial, pharmaceutical and biotechnology

6.3%U.S. academic

(11.8%)Europe

1.5%China

38.2%Pacific Rim

13.9%The Clinical Controls segment includes sales made through R&D Syste
'/>"/>

SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
2. Techne Corporation Releases Unaudited Second Quarter And Six Month Fiscal Year 2013 Results
3. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
4. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
5. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
6. Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014
7. Arrayit Corporation Announces New Corporate Headquarters in Sunnyvale California
8. Psychemedics Corporation Announces Earnings Up 20% And Top Revenue Quarter
9. Comprehensive Care Corporation Announces Extension of $5 Million Credit Facility
10. ARRAYit Corporation Receives $104,000 Purchase Order from the University of California
11. ARRAYit Corporation Ships Proprietary Life Sciences Products to Google Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)... 2014  KIYATEC announced today that it has ... Research (SBIR) Phase II Contract from the National ... and centers that comprise the National Institutes of ... year award, KIYATEC will expand its 3D breast ... forefront of cancer therapy strategies: 1) cancer,s interaction ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... endothelial growth factor (VEGF) agent for wet AMD, is ... Advantage plans as Genentech,s Lucentis, which is the standard ... managed care organization (MCO) directors do not identify a ... slightly more likely than Lucentis to be listed on ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
... 31, 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd ... clinical study to confirm the efficacy of its novel ... trial is evaluating the efficacy, safety and tolerability of ... compared to vehicle. The trial consists of treating 132 ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... BSTC ), a biopharmaceutical company, today announced ... Companies and announced plans to move XIAFLEX forward in ... as well as to collaborate on the initiation of ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8
(Date:9/18/2014)... New York (PRWEB) September 18, 2014 ... lawsuits ( http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s ... have all claims filed on behalf of out-of-state ... motions filed on September 11th, the defendants maintain ... claims contained in the lawsuits have no connection ...
(Date:9/18/2014)... 18, 2014 Memorial Cardiac and ... this week by performing the first ever, adult heart ... Network for Organ Sharing) approval to launch the adult ... only two programs in South Florida. , The ... Enrique Gongora, Medical Director of the Adult Heart ...
(Date:9/18/2014)... people become more physically vulnerable during bereavement, new research ... during bereavement changes with age, British researchers say. As ... likely to have weakened immune systems and develop infections, ... months after loss, we can suffer from reduced neutrophil ... blood cell and as such are essential at combating ...
(Date:9/18/2014)... September 18, 2014 One of the ... medical transport industry, ShandsCair Flight Program’s new ... Inc . (AHI) at the Air Medical Transport Conference ... delivered and placed into service ShandsCair EC155 and the ... be displayed at AMTC highlight Airbus Helicopters broad, industry ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Daily supplements of selenium ... the development of age-related cataracts among men, a new ... one or both could help prevent cataracts. To investigate ... and Harvard Medical School in Boston, and his colleagues ... and vitamin E. The trial was initially designed to ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2
... ... to Sonitor’s Ultrasound RTLS Technology Platform strengthen further the technology’s position as the ... ... Sonitor Technologies, the world leader in ultrasound-based real time locating systems for hospitals ...
... ... ... , ... , , , ...
... patients who regularly received massages averaging 14 minutes or more ... over four weeks, according to results of a study reported ... Society. In the study, sponsored by the National Cancer ... program to provide massage to patients at home. The multi-ethnic ...
... The introduction of prostate-specific antigen (PSA) testing as a screening ... beginning of the 1990s drastically increased the detection of PCa. ... men with PCa. To assess the risk of suicide among ... study was carried out in Sweden. The results are published ...
... Copenhagen, led by postdoc Luke Holman of the Center for ... B , published on the 24 February 2010, that ant ... Often, an ant colony has more than one queen. Multiple ... increasing the chance the colony will survive the hazardous first ...
... ... wristbands market with line of ready-to-ship LaserBand® products that can be instantly priced and ... ... in providing a complete range of printed products and services, today announced the launch ...
Cached Medicine News:Health News:Sonitor Technologies Announces New Staff Tag and Battery Powered Ultrasound Receiver 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 3Health News:Family members reduce stress in advanced cancer patients with 14 minute massages 2Health News:Plotting and treachery in ant royal families 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 3
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: